CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Study Evaluating the Safety of Cirtuvivint as Monotherapy and in Combination With ASTX727 in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06484062
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:29:03.733947+00:00
Published At: 2026-04-24T00:00:00+00:00
Record Updated At: 2026-04-24
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Acute Myeloid Leukemia", "Myelodysplastic Syndrome", "Myelodysplastic Syndrome/Acute Myeloid Leukemia", "Recurrent Acute Myeloid Leukemia", "Recurrent Myelodysplastic Syndrome", "Recurrent Myelodysplastic Syndrome/Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia", "Refractory Myelodysplastic Syndrome", "Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-04-24"
protocolSection.identificationModule.nctId: "NCT06484062"
protocolSection.identificationModule.officialTitle: "A Phase I Study Evaluating the Safety of Cirtuvivint as Monotherapy and in Combination With ASTX727 in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.